Now showing items 1-8 of 8
Cell filtration-laser scanning cytometry for the characterisation of circulating breast cancer cells.
Background Epithelial cells may be detected in the circulation of the majority of patients with metastatic breast cancer. Quantification of such presumptive cancer cells might allow for the monitoring of patients with early ...
Short-term presurgical treatment for all?
(BIOMED CENTRAL LTD, 2007-01-01)
Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience.
De novo resistance to endocrine therapy is a near-universal feature of oestrogen receptor (ER)- negative breast cancer. Although many ER-positive breast cancers also show no response to tamoxifen or aromatase inhibitors ...
Predictors of response to aromatase inhibitors.
Aromatase inhibitors are now considered to be part of the endocrine treatment for most hormone receptor-positive breast cancer in post-menopausal women for both early and advanced disease. Despite the impressive efficacy ...
Enhancing endocrine response with novel targeted therapies: why have the clinical trials to date failed to deliver on the preclinical promise?
Acquired resistance to endocrine therapies has severely limited their long-term effectiveness in breast cancer. In recent years a clear rationale has developed for combining signal transduction inhibitors (STIs) with ...
Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer.
The study of changes in proliferation as a marker of treatment benefit during presurgical endocrine treatment of breast cancer has become increasingly popular, particularly using the nuclear marker Ki67, and holds the ...
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Purpose Neoadjuvant (preoperative) therapy for breast cancer may allow for the development of intermediate markers of treatment benefit, thereby circumventing the need for efficacy trials of adjuvant therapy, which require ...